Direxion Daily Phrmctcl&MdclBl3XShrsETF (PILL)
8.22
+0.08
(+0.98%)
USD |
NYSEARCA |
Mar 28, 16:00
8.22
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
---|---|---|---|
1.01% | 0.20% | 14.77M | 84654.47 |
Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
1.82% | 51.00% | 3.726M | Upgrade |
Basic Info
Investment Strategy | |
The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Mid Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Miscellaneous |
Broad Category | Miscellaneous |
Category Name | Trading--Leveraged Equity |
Category Index | S&P 500 TR USD |
Global Category Name | Trading Tools |
YCharts Categorization | Other |
YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
Prospectus Objective | Growth and Income |
Fund Owner Firm Name | Direxion Funds |
Prospectus Benchmark Index | |
S&P Pharms Select Industry TR USD | 300.0% |
Broad Asset Class Benchmark Index | |
^SPXTR | 100.0% |
Manager Tenure | |
Paul Brigandi | 6.30 yrs |
Tony Ng | 6.30 yrs |
Performance Versus Category
As of March 28, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 28, 2024.
Basic Info
Investment Strategy | |
The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Mid Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Miscellaneous |
Broad Category | Miscellaneous |
Category Name | Trading--Leveraged Equity |
Category Index | S&P 500 TR USD |
Global Category Name | Trading Tools |
YCharts Categorization | Other |
YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
Prospectus Objective | Growth and Income |
Fund Owner Firm Name | Direxion Funds |
Prospectus Benchmark Index | |
S&P Pharms Select Industry TR USD | 300.0% |
Broad Asset Class Benchmark Index | |
^SPXTR | 100.0% |
Manager Tenure | |
Paul Brigandi | 6.30 yrs |
Tony Ng | 6.30 yrs |